Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their development projects utilising Devyser’s unique assays in its CLIA-certified laboratory.

Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

In a recent study published in The Journal of Applied Laboratory Medicine, researchers evaluated the performance of a compact diagnostic assay that can accurately and rapidly diagnose lactose intolerance using capillary blood and buccal swab samples.

Oxford Nanopore Technologies and IQVIA have struck a partnership to broaden access to nanopore sequencing technology, saying it will boost genomics research and patient care.

Laboratory services company Labcorp has accelerated a strategy to drive growth through a string of healthcare system acquisitions and partnerships as its COVID PCR testing volumes have tapered off.

Abbott has received U.S. Food and Drug Administration clearance for its advanced Alinity® h-series hematology system, paving the way for laboratories throughout the country to run complete blood counts (CBC) as a part of Abbott’s Alinity family of diagnostic products.

DiaCarta said Monday that it has formed a strategic partnership with New Jersey-based contract research organization Hopkins MedTech Compliance/Hopkins MedTech Lab Services to provide validation and regulatory compliance services for laboratory test and in vitro diagnostic developers in the US.

AACC has announced that it is changing its name to the Association for Diagnostics & Laboratory Medicine (ADLM).

To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results. By connecting workflow steps within one interface, Diomni Enterprise can increase a lab’s ability to dynamically respond to today’s rapidly changing testing environment. The solution can be used by a variety of labs performing routine quantitative polymerase chain reaction (qPCR) diagnostic tests and by developers to increase the speed of innovation for emerging testing solutions.